Literature DB >> 9316499

Lipoprotein-stimulated surfactant secretion in alveolar type II cells: mediation by heterotrimeric G proteins.

M S Pian1, L G Dobbs.   

Abstract

Low- and high-density lipoproteins (LDL and HDL, respectively) stimulate alveolar type II cells to secrete surfactant. Increases in phosphoinositide hydrolysis, cytosolic Ca2+, and membrane-associated protein kinase C activity precede LDL- and HDL-stimulated secretion. We report three lines of evidence supporting the hypothesis that Gi mediates LDL- and HDL-stimulated surfactant secretion and signal transduction in type II cells. First, pertussis toxin (PTX) inhibited secretion stimulated by the apolipoprotein ligands for either the LDL receptor or the HDL binding protein. Second, PTX inhibited protein kinase C activity in cell membranes stimulated by LDL or HDL. Third, treatment of cell membranes with LDL or HDL inhibited PTX-catalyzed labeling of substrates corresponding in molecular mass to Gi alpha. These observations suggest that receptor-mediated activation of Gi is required for LDL- and HDL-stimulated secretion and that LDL and HDL activate Gi. These studies in type II cells are the first to support the hypothesis that Gi mediates the effects of LDL or HDL on important phenotype-specific functions of differentiated cells.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9316499     DOI: 10.1152/ajplung.1997.273.3.L634

Source DB:  PubMed          Journal:  Am J Physiol        ISSN: 0002-9513


  13 in total

1.  Revisiting "Good" and "Bad" Cholesterol. The Battle over Flow through Arteries Now Shifts to Flow through Airways.

Authors:  Michael B Fessler
Journal:  Am J Respir Crit Care Med       Date:  2015-05-01       Impact factor: 21.405

2.  Roles of the Mevalonate Pathway and Cholesterol Trafficking in Pulmonary Host Defense.

Authors:  Kristin A Gabor; Michael B Fessler
Journal:  Curr Mol Pharmacol       Date:  2017       Impact factor: 3.339

3.  Cholesterol, lipoproteins and subclinical interstitial lung disease: the MESA study.

Authors:  Anna J Podolanczuk; Ganesh Raghu; Michael Y Tsai; Steven M Kawut; Eric Peterson; Rajiv Sonti; Daniel Rabinowitz; Craig Johnson; R Graham Barr; Karen Hinckley Stukovsky; Eric A Hoffman; J Jeffrey Carr; Firas S Ahmed; David R Jacobs; Karol Watson; Steven J Shea; David J Lederer
Journal:  Thorax       Date:  2017-01-27       Impact factor: 9.139

4.  ATP-binding cassette transporter G1 deficiency dysregulates host defense in the lung.

Authors:  David W Draper; Jennifer H Madenspacher; Darlene Dixon; Debra H King; Alan T Remaley; Michael B Fessler
Journal:  Am J Respir Crit Care Med       Date:  2010-04-15       Impact factor: 21.405

5.  Emerging roles for cholesterol and lipoproteins in lung disease.

Authors:  Kymberly M Gowdy; Michael B Fessler
Journal:  Pulm Pharmacol Ther       Date:  2012-06-15       Impact factor: 3.410

6.  Dyslipidemia induces opposing effects on intrapulmonary and extrapulmonary host defense through divergent TLR response phenotypes.

Authors:  Jennifer H Madenspacher; David W Draper; Kathleen A Smoak; Haitao Li; Gary L Griffiths; Benjamin T Suratt; Martha D Wilson; Lawrence L Rudel; Michael B Fessler
Journal:  J Immunol       Date:  2010-06-25       Impact factor: 5.422

7.  Next stop for HDL: the lung.

Authors:  M B Fessler
Journal:  Clin Exp Allergy       Date:  2012-03       Impact factor: 5.018

8.  Low-density-lipoprotein-receptor-related protein (LRP) interacts with a GTP-binding protein.

Authors:  L Goretzki; B M Mueller
Journal:  Biochem J       Date:  1998-12-01       Impact factor: 3.857

9.  Alveolar type I cells protect rat lung epithelium from oxidative injury.

Authors:  Jiwang Chen; Zhongming Chen; Narendranath Reddy Chintagari; Manoj Bhaskaran; Nili Jin; Telugu Narasaraju; Lin Liu
Journal:  J Physiol       Date:  2006-05-01       Impact factor: 5.182

10.  High-Density Lipoprotein Cholesterol: A Component of the Metabolic Syndrome with a New Role in Lung Function.

Authors:  Faxuan Wang; Di Tian; Yi Zhao; Jiangping Li; Xiyuan Chen; Yuhong Zhang
Journal:  Evid Based Complement Alternat Med       Date:  2021-06-02       Impact factor: 2.629

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.